TACE-HACI + atezolizumab + bevacizumab

This is a combination therapy for liver cancer (primarily hepatocellular carcinoma) that includes: - Transarterial chemoembolization with hepatic arterial chemotherapy infusion (TACE-HACI): a minimally invasive procedure where chemotherapy drugs are delivered directly to the liver tumor via the hepatic artery, followed by embolic agents to block blood flow, maximizing local drug concentration and starving the tumor of nutrients[1][2][3][7]. - Atezolizumab: an immune checkpoint inhibitor targeting PD-L1, enhancing anti-tumor immune response. - Bevacizumab: a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis. This combination leverages locoregional cytotoxicity from TACE-HACI with systemic immunotherapy and antiangiogenic effects. It is being investigated for improved outcomes in intermediate or advanced hepatocellular carcinoma compared to standard therapies[5].

Other names

TACE-HACI plus atezolizumab and bevacizumabTACE plus hepatic arterial chemotherapy infusion plus atezolizumab and bevacizumab